

7 Literaturverzeichnis

1. **Algire G.H. (1945)** Vascular reactions of normal and malignant tissues in vivo. I. Vascular reactions of mice to wounds and to normal and neoplastic transplants. *J. Natl Cancer Inst. USA* **6**, 73-85
2. **Asahara T. et al (1997)** Isolation of putative progenitor endothelial cells for angiogenesis. *Science* **275**, 964-967
3. **Asahara T. et al (1999)** Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularisation. *Circ. Res.* **85**, 221-228
4. **Banks E. et al (2004)** Influence of personal characteristics of individual women on sensitivity and specificity of mammography in the Million Women Study: cohort study. *BMJ* **329**, 477
5. **Bergers G., Benjamin L. (2002)** Tumorigenesis and the angiogenic switch. *Nature Reviews Cancer* Vol **3**, 401-410
6. **Bertolini F. et al (2003)** Maximum Tolerable Dose and Low-Dose Metronomic Chemotherapy Have Opposite Effects on the Mobilization and Viability of Circulating Endothelial Progenitor Cells. *Cancer Research* **63**, 4342-4346
7. **Cameliet P., Jain R. (2000)** Angiogenesis in cancer and other diseases. *Nature* **407**, 249-257
8. **Chang Y.S. et al (2000)** Abundance of neoplastic cells in vessel walls of human tumor xenografts. *Proc. Am. Assoc. Cancer Res.*
9. **Clark D.E., Smith S.K., He Y. et al. (1998)** A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation. *Biology of Reproduction* **59**, 1540-1548

10. **Clark P., Boswell F., Greer I. (1998)** The neutrophil and preeclampsia. *Seminars in Reproductive Endocrinology*; Vol **16**
11. **Cuevas P., Barrios V., Gimenez-Gallego G. et al (1997)** Serum levels of basic fibroblast growth factor in acute myocardial infarction. *Eur J Med Res* **2**, 282-284
12. **Dimmeler S. et al (2001)** HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. *J. Clin. Invest.* **108**, 391-397
13. **Dirix L.Y. et al (1997)** Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients. *Brit. J. Cancer* **76**, 238-243
14. **Ehrmann R.L., Knoth M. (1968)** Choriocarcinoma: transfilter stimulation of vasoproliferation in the hamster cheek pouch studied by light and electron microscopy. *J. Natl Cancer Inst.* **41**, 1329-1341
15. **Eichhorn M.E., Strieth S., Dellian M. (2004)** Anti-vascular tumor therapy: recent advances, pitfalls and clinical perspectives. *Drug Resistance Updates* **7**, 125-138
16. **Fernig DG., Smith JA., Rudland PS. (1991)** Relationship of growth factors and differentiation in normal and neoplastic development of the mammary gland. *Cancer Treat Res* **53**, 47-78
17. **Fiedler W., Gehling U., Mende T., Hossfeld D.K. (2001)** Neoangiogenese und Tumorwachstum, Pathophysiologie und neue therapeutische Ansätze. *Deutsches Ärzteblatt* 2001, Jg.98, **21**, 1392-1394
18. **Folkman J. (1971)** Tumor angiogenesis: therapeutic implications. *New Engl J Med* **285**, 1182-6
19. **Folkman J. (2000)** Tumor angiogenesis. *Cancer medicine* 2546pp

20. **Folkman J. (2001)** Can mosaic tumor vessels facilitate molecular diagnosis of cancer. *PNAS* **98**, 398-400
21. **Folkman J. (2003)** Angiogenesis and apoptosis. *Seminars in Cancer Biology* **13**, 159-167
22. **Gehling U.M. (2000)** In vitro differentiation of endothelial cells from AC133-positive progenitor cells. *Blood* **95**, 3106-3112
23. **Gilead A., Neeman M. (1999)** Dynamic remodelling of the vascular bed precedes tumor growth: MLS ovarian carcinoma spheroids implanted in nude mice. *Neoplasia* **1**, 226-230
24. **Gill M. et al (2001)** Vascular Trauma Induces Rapid but Transient Mobilization of VEGFR2⁺ AC133⁺ Endothelial Precursor Cells. *Circ Res.* **88**, 167-174
25. **Goldman E. (1907)** The growth of malignant disease in man and the lower animals with special reference to the vascular system. *Lancet* **2**, 1236-1240
26. **Granato A.M. (2003)** Basic fibroblast growth factor and vascular endothelial growth factor serum levels in breast cancer patients and healthy woman: useful as diagnostic tools? *Breast Cancer Research* Vol.6 **1**, R38-R45
27. **Greenblatt M., Shubik P. (1968)** Tumor angiogenesis: transfilter diffusion studies in the hamster by the transparent chamber technique. *J.Natl Cancer Inst.* **41**, 111-124
28. **Hanahan D., Folkman J. (1996)** Patterns and Emerging Mechanisms Review of the Angiogenic Switch during Tumorigenesis. *Cell* **86**, 353-364
29. **Harstrick A., Perschl A. (2000)** Tumorangiogenese – Therapiekonzepte *Onkologie* **6**, 443-449
30. **Heissig B. et al (2002)** Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. *Cell* **109**, 625-637

31. **Heits F., Katschinski D.M., Wiedemann G.J., Weiss C., Jelkmann W. (1997)** Serum vascular endothelial growth factor, a prognostic indicator in sarcoma and carcinoma patients. *Int. J. Oncol.* **10**, 333-337
32. **Heits F., Wiedemann G.J., Jelkmann W. (1998)** Der vaskuläre endotheliale Wachstumsfaktor VEGF stimuliert die Angiogenese im Guten wie im Bösen. *Dtsch med Wschr* **123**, 259-265
33. **Hellstrom M. et al (2001)** Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis. *J Cell Biol* **153**, 543-554
34. **Helmlinger G., Yuan F., Dellian M., Jain R.K. (1997)** Interstitial pH and pO₂ gradients in solid tumors in vivo:high-resolution measurements reveal a lack of correlation. *Nature Med* **3**, 177-182
35. **Hirschi K.K., D'Amore P.A. (1996)** Pericytes in the microvasculature. *Cardiovascular Research* **32**, 687-698
36. **Hristov M., Erl W., Weber P. (2003)** Endothelial Progenitor Cells:Mobilization, Differentiation, and Homing. *Arterioscler Thromb Vasc Biol.* Vol **23**
37. **Ide A.G. (1939)** Vascularization of the Brown-Pearce rabbit epithelioma transplant as seen in the transparent ear chamber. *Am. J. Radial.* **42**, 891-899
38. **Jin-No K. et al (1997)** Plasma level of basic fibroblast growth factor increases with progression of chronic liver disease. *J Gastroenterol* **32**, 119-121
39. **Ikeda E., Achen M.G., Breier G., Risau W. (1995)** Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells. *J Biol Chem* **270**, 19761-19766
40. **Kalka C. et al (1999)** Vascular endothelial growth factor (VEGF): therapeutic angiogenesis and vasculogenesis in the treatment of cardiovascular disease. *Med Klin* **94**, 193-201

41. **Kalka C. et al (2000)** Vascular Endothelial Growth Factor₁₆₅ Gene Transfer Augments Circulating Endothelial Progenitor Cells in Human Subjects. *Circ Res.* **86**, 1198-1202
42. **Kerbel R., Folkman J. (2002)** Clinical translation of angiogenesis inhibitors. *Nat. Rev. Cancer* **2**, 727-739
43. **Kondo S. et al (1994)** Vascular endothelial growth factor/vascular permeability factors is detectable in the sera of tumor-bearing mice and cancer patients. *Biochim. Biophys. Acta* **1221**, 211-214
44. **Kraft A. et al (1999)** Vascular Endothelial Growth Factor in the Sera and Effusions of Patients with Malignant and Nonmalignant Disease. *Cancer* **85**, 178-87
45. **Kroll J., Waltenberger J. (2000)** Regulation der Endothelfunktion und der Angiogenese durch den vaskulären endothelialen Wachstumsfaktor-A (VEGFA). *Z Kardiol* **89**, 206-218
46. **Leu A. (2000)** Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation. *Cancer Res.* **60**, 4324-4327
47. **Lin Y. et al (2000)** Origins of circulating endothelial cells and endothelial outgrowth from blood. *J. Clin. Invest.* **105**, 71-77
48. **Lindahl P. et al (1998)** Endothelial-perivascular cell signaling in vascular development: lessons from knockout mice. *Curr Opin Lipidol* **9**, 407-411
49. **Luttun A. et al (2002)** Revascularization of ischemic tissues by PIGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. *Nature med.* **8**, 831-840

50. **Lyden D. et al (2001)** Impaired recruitment of bone-marrow-derived endothelial and haematopoietic precursor cells blocks tumor angiogenesis and growth. *Nature med.* **7**, 1194-1201
51. **Mancuso P. et al (2001)** Rested and activated endothelial cells are increased in the peripheral blood of cancer patients. *Blood* **97**, 3658-3661
52. **McLeskey SW. et al (1994)** MDA-MB-134 breast carcinoma cells overexpress fibroblast growth factor (FGF) receptors and are growth-inhibited by FGF ligands. *Cancer Res* **54**, 523-530
53. **Monestiroli S. et al (2001)** Kinetics and variability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma. *Cancer Res.* **61**, 4341-4344
54. **Morikawa S. et al (2002)** Abnormalities in Pericytes on Blood Vessels and Endothelial Sprouts in Tumors. *Am J Pathol* **160**, 985-1000
55. **Olofsson B. et al (1999)** Current biology of VEGF-B and VEGF-C. *Curr. Opin. Biotechnol.* **10**, 528-535
56. **Patan S. (1996)** Intussusceptive microvascular growth in a human colon adenocarcinoma xenograft: a novel mechanism of tumor angionesis. *Microvasc. Res.* **51**, 260-270
57. **Peichev M. et al (2000)** Expression of VEGFR-2 and AC133 by circulating human CD34⁺ cells identifies a population of functional endothelial precursors. *Blood* **95**, 952-958
58. **Pichon MF. et al (2000)** Serum bFGF (Basic Fibroblast Growth Factor) and CA15.3 in the Monitoring of Breast Cancer Patients. *Anticancer Research* **20**, 1189-1194
59. **Rafii S. (1994)** Isolation and characterisation of human bone marrow microvascular endothelial cells: hematopoietic progenitor cell adhesion. *Blood* **84**, 10-18

60. **Rafii S. (2002)** Vascular and haematopoietic stem cells: Novel targets for anti-angiogenesis therapy?. *Nature Reviews, Cancer* **2**, 826-834
61. **Rafii S. (2003)** Angiogenic factors reconstitute hematopoiesis by recruiting stem cells from bone marrow microenviromet. *Ann. N.Y. Acad. Sci.* **996**, 49-60
62. **Reyes M. (2002)** Origin of endothelial progenitors in human postnatal bone marrow. *J. Clin. Invest.* **109**, 337-346
63. **Risau W., Flamme I. (1995)** Vasculogenesis. *Ann Rev Cell Dev Biol* **11**, 73-91
64. **Risau W. (1997)** Mechanisms of angiogenesis. *Nature* **386**, 671-674
65. **Robson M.E., Offit K. (2004)** Breast MRI for Women With Hereditary Cancer Risk. *JAMA* **282**, 1317-1325
66. **Salven P. (1999)** Serum VEGF levels in women with a benign breast tumor or breast cancer *Breast Cancer Research and Treatment* **53**, 161-166
67. **Salven P. (2003)** VEGFR-3 and CD133 identify a population of CD34⁺ lymphatic/vascular endothelial precursor cells. *Blood* **101**, 168-172
68. **Sawano A. (2001)** Flt-1, vascular endothelial growth factor receptor 1, is a novel cell surface marker for the lineage of monocyte-macrophages in humans. *Blood* **97**, 785-791
69. **Schumm M. et al (1999)** Isolation of Highly Purified Autologous and Allogeneic Peripheral CD34⁺ Cells Using the CliniMACS Device. *Journal of Hematootherapy* Vol 8, **2**, 209-218
70. **Shen H., Clauss M., Ryan J., Schmidt A-M., Tjiburg P. et al. (1993)** Characterisation of vascular permeability factor/vascular endothelial growth factor receptors on mononuclear phagocytes. *Blood* **10**, 2767-2773

71. **Sliutz G., Tempfer C., Obermair A., Dadak CH., Kainz CH. (1995)** Serum Evaluation of Basic FGF in Breast Cancer Patients. *Anticancer Research* **15**, 2675-2678
72. **Takei Y., Kurobe M., Uchida A., Hayashi K. (1994)** Serum Concentrations of Basic Fibroblast Growth Factor in Breast Cancer. *Clinical Chemistry* Vol 40, **10**, 1980-1981
73. **Toi M. et al (1996)** Quantitative Analysis of Vascular Endothelial Growth Factor in Primary Breast Cancer. *Cancer* **77**, 1101-110
74. **Vasa M. et al (2001)** Number and Migratory Activity of Circulating Endothelial Progenitor Cells Inversely Correlate With Risk Factors for Coronary Artery Disease *Circ. Res.* **89**,e1-e7
75. **Yamamoto Y. (1996)** Concentrations of vascular endothelial growth factor in sera of normal controls and cancer patients. *Clin. Cancer Res.* **2**, 821-826
76. **Yancopoulos G.D. et al (2000)** Vascular-specific growth factors and blood vessel formation. *Nature* **407**, 242-248
77. **Yin A.H. et al (1997)** AC133, a novel marker for human hematopoietic stem and progenitor cells. *Blood* **90**, 5002-5012
78. **Ziegler B.L. et al (1999)** KDR Receptor: A Key Marker Defining Hematopoietic Stem Cells. *Science* **285**, 1553-1558